Niagen Bioscience Inc (NAGE)

Currency in USD
3.400
+0.080(+2.41%)
Closed·
3.440+0.040(+1.18%)
·
Advertisement
Earnings results expected tomorrow
NAGE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.2103.410
52 wk Range
3.11511.290
Key Statistics
Prev. Close
3.4
Open
3.32
Day's Range
3.21-3.41
52 wk Range
3.115-11.29
Volume
648.54K
Average Volume (3m)
853.03K
1-Year Change
-62.3894%
Book Value / Share
1.03
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAGE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.417
Upside
+265.20%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Niagen Bioscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.417
(+265.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Canaccord
Buy10.00+194.12%-Maintain10/07/2026
H.C. Wainwright
Buy11.00+223.53%-Maintain09/07/2026
Freedom Broker
Buy9.00+164.71%-New Coverage06/07/2026
H.C. Wainwright
Buy11.00+223.53%-Maintain01/07/2026
H.C. Wainwright
Buy11.00+223.53%12.00Maintain11/05/2026

Niagen Bioscience Inc Earnings Call Summary for Q3/2025

  • Niagen Bioscience (NAGE) exceeded Q3 2025 forecasts with EPS of $0.05 vs $0.02 expected and revenue of $34M vs $30.83M expected, despite stock dipping 3.73% after hours.
  • Revenue grew 33% year-over-year to $34M with net income rising to $4.6M from $1.9M in Q3 2024, driven by a 109% increase in distribution business.
  • Gross margin improved to 64.5% (up 100 basis points), with the company maintaining a strong cash position of $64.3M and no debt.
  • Management revised full-year revenue growth guidance to 25-30%, announcing plans to launch a telehealth platform for at-home injections by mid-2026.
  • Key challenges include regulatory hurdles like the FDA's NMN ruling, intense competition in NAD precursor products, and potential economic pressures on consumer spending.
Last Updated: 04/11/2025, 22:34
Read Full Transcript

Earnings

Latest Release
06/05/2026
EPS / Forecast
0.07 / 0.08
Revenue / Forecast
31.5M / 30.23M
EPS Revisions
Last 90 days

Compare NAGE to Peers and Sector

Metrics to compare
NAGE
Peers
Sector
Relationship
P/E Ratio
14.6x−2.2x11.6x
PEG Ratio
0.840.010.03
Price/Book
3.3x2.9x1.5x
Price / LTM Sales
2.1x2.2x0.9x
Upside (Analyst Target)
223.5%12.9%23.7%
Fair Value Upside
Unlock10.7%13.9%Unlock

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.86M14.85%40.31M
Other Institutional Investors
29.11M36.48%98.98M
Public Companies & Retail Investors
38.84M48.67%132.07M
Total
79.81M100.00%271.36M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.5.21%4,161,62614,150
SteelPeak Wealth, LLC4.39%3,500,12911,900

People Also Watch

36.810
RIGL
-3.28%
1.2200
DARE
-1.61%
8.080
XERS
-4.04%
9.92
TSSI
+1.85%

FAQ

What Is the Niagen Bioscience (NASDAQ: NAGE) Share Price Today?

The Niagen Bioscience stock price today is 3.400 USD.

What Stock Exchange Does Niagen Bioscience (NAGE) Trade On?

Niagen Bioscience is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Niagen Bioscience?

The stock symbol (also called a 'ticker') for Niagen Bioscience is "NAGE."

What Is the Current Niagen Bioscience Market Capitalisation?

As of today, Niagen Bioscience (NASDAQ: NAGE) market cap is 271.360M USD.

What Is Niagen Bioscience's (NAGE) Earnings Per Share (TTM)?

The Niagen Bioscience EPS is currently 0.210 (Trailing Twelve Months).

When Is the Next Niagen Bioscience Earnings Date?

Niagen Bioscience's next earnings report will be released on 04/08/2026.

Is NAGE a Buy or Sell From a Technical Analyst Perspective?

Based on today's Niagen Bioscience moving averages and other technical indicators, the daily buy/sell signal for NAGE stock is Neutral.

How Many Times Has Niagen Bioscience Stock Split?

Niagen Bioscience has split 1 times. (See the NAGE stock split history page for full effective split date and price information.)

How Many Employees Does Niagen Bioscience Have?

Niagen Bioscience has 117 employees, based on their latest Companies House report.

What is the current trading status of Niagen Bioscience (NASDAQ: NAGE)?

As of 03/08/2026, Niagen Bioscience (NAGE) is trading at a share price of 3.400 USD, with a previous close of 3.400 USD. The stock has fluctuated within a day range of 3.210 USD to 3.410 USD, while its 52-week range spans from 3.115 USD to 11.290 USD.

What Is Niagen Bioscience (NAGE) Price Target According to Analysts?

The average 12-month price target for Niagen Bioscience is 12.417 USD, with a high estimate of 22 USD and a low estimate of 8.5 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +265.20% Upside potential.

What Is the NAGE Premarket Price?

NAGE's last pre-market stock price is 3.440 USD. The pre-market share volume is 1,240.000, and the stock has decreased by 0.040, or 1.180%.

What Is the NAGE After Hours Price?

NAGE's last after hours stock price is 3.370 USD, the stock has decreased by -0.030, or -0.880%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.